BOSTON, April 03, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its Phase 1a clinical trial of TTX-MC138, an experimental therapy targeting ...

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. Unlock your all-in-one trading dashboard with real-time alerts ...

BOSTON, May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...

BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today ...

TransCode Therapeutics Inc RNAZ shares are trading higher Thursday after the company announced it received written authorization from the FDA to proceed with its First-in-Human Phase 0 clinical ...

BOSTON, March 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), ("TransCode" or the "Company"), the RNA oncology company committed to more effectively treating cancer using RNA ...

The therapeutic candidate being evaluated, TTX-MC138, is TransCode’s lead candidate designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer.

This is one reason why TransCode Therapeutics’ stock is falling today. On top of that, the public offering price is a significant discount over its prior closing price of 79 cents.